RT Journal Article
SR Electronic
T1 HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.05.23299513
DO 10.1101/2023.12.05.23299513
A1 Karakosta, Argyro
A1 Ruiz-Burga, Elisa
A1 Tariq, Shema
A1 Touloumi, Giota
A1 Nicholls, Emily Jay
A1 Pantazis, Nikos
A1 Jarrin, Inma
A1 Van der Valk, Marc
A1 Sabin, Caroline
A1 Mussini, Christina
A1 Meyer, Laurence
A1 Anne, Alain Volny
A1 Carlander, Christina
A1 Grabar, Sophie
A1 Wittkop, Linda
A1 Spire, Bruno
A1 Gill, Jonh
A1 Porter, Kholoud
A1 Burns, Fiona
A1 CASCADE Collaboration
YR 2023
UL http://medrxiv.org/content/early/2023/12/07/2023.12.05.23299513.abstract
AB Background Individuals who have recently acquired HIV represent a unique population because the time frame since HIV acquisition is relatively short and identification of missed HIV prevention opportunities is, therefore, closer to real time and less subject to recall bias. Identifying prevention measures used and missed opportunities for using them, can help stop further HIV transmission.Objectives This systematic review aims to synthesise current global evidence on uptake of HIV prevention methods among people with recently acquired HIV from 2007, the year that the concept of ART as a prevention method was first introduced.Methods and analysis MEDLINE/PubMed, EMBASE, PsycINFO, Cochrane and Web of Science databases, will be searched for articles published January 2007 - July 2023. Eligible studies will be those that reported on HIV prevention methods among people with recently acquired HIV. Quality assessment of the studies selected will be undertaken, and reporting of the systematic review will be informed by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results The results of the systematic review will be available by the end of January 2024.Conclusions The findings will be of key relevance to researchers, healthcare providers including third sector organisations/ community groups and policymakers, as they will offer insight into better understanding of missed or failed HIV prevention efforts and will help ensure future efforts meet the needs of those in need of them.Competing Interest StatementConflicts of interest The funders did not participate in the study design and will not intervene in its process, analysis or publication of the findings. ST has received speaker honoraria and consultancy fees from Gilead Sciences. CC has received speaker/moderator honoraria and advisory board fees from Gilead Sciences, GSK/ViiV and MSD as well as an unrestricted Gilead Sciences Nordic Fellowship Research Grant. CS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for participation in Advisory Boards, speaker panels and for preparation of educational materials. MVdV has received consultancies fees for participation in advisory boards and research grants from Gilead, MSD and ViiV all paid to his institution. FB has received funding from Gilead Sciences Ltd for preparation and delivery of educational materials. IJ has received teaching fees from ViiV Healthcare and advisory fees from Gilead Sciences. GT has received research grants and advisory board fees from Gilead, all paid to her institution, and MJG has received honoraria for ad hoc participation in national Advisory boards of Gilead Merck and ViiV.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval is not required for a systematic review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study.HIVHuman Immunodeficiency VirusARTAntiretroviral TherapyPrEPPre-Exposure ProphylaxisTasPTreatment as PreventionAHIAcute HIV InfectionPHIPrimary HIV InfectionPRISMA-PPreferred Reporting Items for Systematic Review and Meta-Analysis ProtocolsPRISMAPreferred Reporting Items for Systematic Review and Meta-AnalysisPEPPost Exposure ProphylaxisOSPOpioid Substitution TherapyRCTsRandomized controlled trialsNOSNewcastle Ottawa Scale